Chromatograms of casein concentrates of goat milk produced by the Alpine and Saanen breeds in Northeastern Brazil using RP-HPLC.

<p>Image A: Casein concentrate from Alpine breed. Image B: Casein concentrate from Saanen breed. (1) κ-casein, (2) αs2-casein, and (3) β-casein.</p

Comparison of two-dimensional electrophoresis of goat crude protein extract milk produced by the Alpine (AM) and Saanen (SM) breeds in Northeastern Brazil.

<p>The vertical direction shows the molecular mass in kDa, and the horizontal direction shows the isoelectric focusing at pH 4–7. A: Molecular markers: BSA (66.0 kDa), egg albumin (45.0 kDa), carbonic anhydrase (30.0 kDa), trypsin inhibitor (23.3 kDa) and egg lysozyme (14.0 kDa). Gels were Coomassi stained.</p

Electrophoretic analyses of goat milk proteins produced by the Alpine and Saanen breeds in Northeastern Brazil precipitated with ammonium sulfate, analyzed by gradient (7 to 20%) SDS-PAGE.

<p>Image A: Alpine breed. (M) Molecular markers*, (A) Crude protein extract, (B) Fraction F_0−30%, (C) Fraction F_30−60%, (D) Fraction F_60−90%, and (E) Fraction F_90−100%. Image B: Saanen breed. (M) Molecular Markers*, (A) Crude protein extract (B) Fraction F_0−30%, (C) Fraction F_30−60%, (D) Fraction F_60−90%, and (E) Fraction F_90−100%. * BSA (66.0 kDa), egg albumin (45.0 kDa), carbonic anhydrase (30.0 kDa), trypsin inhibitor (23.3 kDa) and egg lysozyme (14.0 kDa).</p

Gradient SDS-PAGE (7 to 20%) analyses of goat milk produced by the Alpine and Saanen breeds in Northeastern Brazil.

<p>(M) Molecular markers*, (A) Alpine crude protein extract, (B) Saanen crude protein extract, (C) casein concentrate from Alpine milk, and (D) casein concentrate from Saanen milk. * BSA (66.0 kDa), egg albumin (45.0 kDa), carbonic anhydrase (30.0 kDa), trypsin inhibitor (23.3 kDa) and egg lysozyme (14 kDa).</p

Plasma kallikrein activity – PKA (A), Bradykinin – BK (B) and DesArg⁹-BK (C) at rest and post-exercise recovery period (rec15 and rec45 min) for type 2 diabetic (T2D) and non-diabetic (ND) groups.

<p>*= p<0.05 in relation to T2D at rec15; †= p<0.05 in relation to T2D at rec45.</p

Systolic blood pressure (SBP), diastolic blood pressure (DBP) and mean arterial pressure (MAP) at rest and post-exercise recovery period (rec15, rec30 and rec45 min) for type 2 diabetic (T2D) and non-diabetic (ND) groups.

<p>*= p≤0.05 in relation to rest; †= p≤0.05 in relation to T2D group.</p

Anthropometric and hemodynamic characteristics of the subjects (n = 13) before and after the training program (mean ± SD).

<p>*Statistically significant (p≤0.05).</p><p>Anthropometric and hemodynamic characteristics of the subjects (n = 13) before and after the training program (mean ± SD).</p

Flow-chart of the participants.

<p>Flow-chart of the participants.</p

Evaluation of Interleukin-10 (IL-10), osteoprotegerin (OPG), interleukin-6 (IL-6) and interleukin-12 (IL-12) concentrations before and after the training program (mean ± SD).

<p>*Statistically significant (p≤0.05).</p><p>Evaluation of Interleukin-10 (IL-10), osteoprotegerin (OPG), interleukin-6 (IL-6) and interleukin-12 (IL-12) concentrations before and after the training program (mean ± SD).</p

SF-36 scores before and after the training program (mean ± SD).

<p>*Statistically significant (p≤0.05).</p><p>SF-36 scores before and after the training program (mean ± SD).</p